CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 3, 2002, Pages 196-204

  García Martín, Elena ^a,b,c,d,e   Martínez, Carmen ^a,b,c,d,e   Pizarro, Rosa M ^a,b,c,d,e   García Gamito, Francisco J ^a,b,c,d,e   Gullsten, Harriet ^a,b,c,d,e   Raunio, Hannu ^a,b,c,d,e   Agúndez, José A G ^a,b,c,d,e  

^a School of Sciences   (Spain)

^b Department of Pharmacology   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GENOMIC DNA; ISOENZYME;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; FINLAND; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; SPAIN;

ADULT; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS;

EID: 0036221255     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121371     Document Type: Article

References (35)

1. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
2. Cytochrome P-450 3A4: Regulation and role in drug metabolism
3. Pharmacogenomics: Translating functional genomics into rational therapeutics
4. Substrates of human hepatic cytochrome P450 3A4
5. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities
6. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
7. Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene
8. Interindividual differences in hepatic expression of CYP3A: Relationship to genetic polymorphism in the 5′-upstream regulatory region
9. In vitro and in vivo drug interactions involving human CYP3A
10. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
11. Association of CYP3A4 genotype with treatment-related leukemia
12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
13. Novel mutations of CYP3A4 in Chinese
14. Identification and functional characterization of eight CYP3A4 protein variants
15. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4
16. Aminopyrine N-demethylase activity in human liver microsomes
17. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
18. Modulation of midazolam 1-hydroxylation activity in vitro by neuro-transmitters and precursors
19. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
20. A routine method for the establishment of permanent growing lymphoblastoid cell lines
21. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
22. CYP2D6- and CYP3A4-dependent metabolism of dextromethorphan in humans
23. Detection of MboII polymorphism at the 5′ promoter region of CYP3A4
24. Genetic polymorphism of debrisoquine oxidation: Analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification
25. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
26. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype
27. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity
28. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
29. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening
30. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients
31. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation
32. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil
33. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
34. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
35. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes